Lansap in treatment of esophagitis in patients with systemic sclerosis

Abstract

Objective. To study the efficacy of Lansap (Lansoprasole) in treatment of esophagitis in pts with systemic sclerosis (SS). Methods. 30 SS pts with clinical manifestations and endoscopic signs of esophagitis received lansap 30 or 60 mg/day during two weeks. All pts had a standard endoscopic examination before and after the treatment. Results. Clinical symptoms of esophagitis were reduced significantly in most pts during the first day of treatment and resolved completely to the eleventh day. Endoscopic examination after two weeks revealed decrease of esophagitis severity in all pts. Esophagial erosions were healed in 16 from 18 pts. Conclusion. Lansap is an effective drug for treatment of reflux esophagitis in pts with SS.

Keywords

• systemic sclerosis
• esophagitis
• lansap